CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate: A Chart Review of Spanish Adults with Attention-Deficit Hyperactivity Disorder

Ramos-Quiroga, Josep Antoni, Bosch, Rosa, Castells, Xavier, Valero, Sergi, Nogueira, Mariana, Gómez, Nuria, Yelmo, Silvia, Ferrer, Marc, Martínez, Yolanda, Casas, Miguel · 2008 · CNS Drugs

Abstract

Background The potential advantages of osmotic-release oral system (OROS) methylphenidate (Concerta) over immediate-release (IR) methylphenidate (Rubifen) in adults with attention-deficit hyperactivity disorder (ADHD), with respect to medication adherence, effectiveness and tolerability, are yet to be determined.Objective To compare the adherence, effectiveness and tolerability of OROS methylphenidate versus IR methylphenidate in adults with ADHD. It was hypothesized (after data collection) that adherence and effectiveness would be higher with OROS methylphenidate than with the IR formulation.Study design A chart review was carried out from April 2004 until April 2005.Setting Adult ADHD outpatient program in a general hospital in Spain.Patients Seventy adults with ADHD who met DSM-IV-TR criteria and who did not have any other current major psychiatric disorder.Intervention Patients were treated with IR methylphenidate three times daily for 3 months and then switched to OROS methylphenidate once daily.Main outcome measure Effectiveness was assessed by means of the ADHD rating scale-IV (ADHD-RS-IV) and the Clinical Global Impression-Improvement (CGI-I) scale at 3 months (coinciding with treatment switch) and at 6 months. The Simplified Medication Adherence Questionnaire (SMAQ) was used to assess treatment adherence, and was administered at both 3 and 6 months.Results Seventy adult ADHD patients (mean age +/- SD: 30 +/- 9.6 years; n = 48 men [68.6%]) were included in this study. The mean baseline ADHD-RS-IV score was 34.6 (SD = 10.9). The mean daily dose of IR methylphenidate was 52.1 mg (SD = 13.8 mg) administered as three divided doses. After the treatment switch, the mean OROS methylphenidate daily dose was 57.9 mg (SD = 16.5 mg) administered once daily. The switch from IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire. OROS methylphenidate was more effective than IR methylphenidate (p = 0.0005) in reducing symptoms of ADHD. The percentage of responders was 28.6% with IR methylphenidate and 91.4% with the OROS formulation (p = 0.0005). OROS methylphenidate was preferred by 97% of patients. The most common adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate). No patients stopped treatment with methylphenidate because of adverse events.Conclusions The switch from IR to OROS methylphenidate was associated with an improvement in both adherence and effectiveness. There were no differences between IR and OROS methylphenidate in terms of tolerability.

Overview

Integrity signals

Registry

Crossref · 10.2165/00023210-200822070-00005

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Research works printed but not linked: 3

  1. Biederman, 2006, MedGenMed, 8, 12
  2. Schachter, 2001, CMAJ, 165, 1475
  3. Steele, 2006, Can J Clin Pharmacol, 13, e50

Cited by

See all 64

Metadata

Authors
Ramos-Quiroga, J. A., Bosch, R., Castells, X., Valero, S., Nogueira, M., Gómez, N., Yelmo, S., Ferrer, M., Martínez, Y., & Casas, M.
Affiliations
  • Vall d'Hebron Hospital Universitari (ES)
  • Universitat Autònoma de Barcelona (ES)
Venue
CNS Drugs
Published
2008
Volume
22
Issue
7
Pages
603-611
ISSN
1172-7047 (ISSN-L)
OpenAlex
W2197133068
Cited by
54
References
31
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 7 · 2016: 1 · 2015: 3 · 2014: 3 · 2013: 5 · 2012: 5
FWCI
5.37
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Keywords
OROS methylphenidate, immediate-release methylphenidate, sustained-release formulation, osmotic-release oral system, adult ADHD, medication adherence, treatment effectiveness, tolerability, treatment switching, ADHD Rating Scale-IV, CGI-I, Simplified Medication Adherence Questionnaire, stimulant medication, ADHD medication
MeSH terms
Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Chemistry, Pharmaceutical, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Methylphenidate, Outpatients, Retrospective Studies, Spain, Time Factors, Infusion Pumps, Implantable, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate: A Chart Review of Spanish Adults with Attention-Deficit Hyperactivity Disorder. https://app.cochat.ai/papers/10.2165/00023210-200822070-00005
The paper
Ramos-Quiroga, J. A., Bosch, R., Castells, X., Valero, S., Nogueira, M., Gómez, N., Yelmo, S., Ferrer, M., Martínez, Y., & Casas, M. (2008). Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate: A Chart Review of Spanish Adults with Attention-Deficit Hyperactivity Disorder. CNS Drugs. https://doi.org/10.2165/00023210-200822070-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.